JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, G. P.
Right arrow Articles by Pasternak, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, G. P.
Right arrow Articles by Pasternak, G. W.

Vol. 282, Issue 3, 1291-1297, 1997

3H-Morphine-6beta -Glucuronide Binding in Brain Membranes and an MOR-1-Transfected Cell Line1

George P. Brown, Ke Yang, Ouathek Ouerfelli, Kelly M. Standifer, David Byrd and Gavril W. Pasternak

The Cotzias Laboratory of Neuro-Oncology, Memorial Sloan-Kettering Cancer Center (G.P.B., K.Y., O.O., D.B., G.W.P.), and Department of Neurology and Neuroscience, Cornell Uuniversity Medical College (G.W.P.), New York, and Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston Texas (K.M.S.)

Morphine-6beta -glucuronide (M6G) is a potent morphine metabolite. In an effort to further explore its mechanisms of action, we synthesized 3H-M6G of high specific activity and examined its binding. Although its affinity toward traditional mu receptors is similar to morphine in binding assays in brain and in Chinese hamster ovary cells stably transfected with MOR-1, M6G is >100-fold more potent than morphine in analgesic assays. This apparent discrepancy cannot be explained by differing intrinsic activities of the two drugs because both agents are partial agonists with similar efficacies in adenylyl cyclase assays in the transfected cell lines. Behavioral studies have implied the possibility of a distinct M6G receptor. Detailed binding studies in brain tissue reveal evidence for heterogeneity. Nonlinear regression analysis of 3H-M6G saturation studies reveals two components. The lower-affinity component (KD = 1.93 ± 0.6 nM) corresponds to labeling of traditional mu receptors. In addition, 3H-M6G labels another site of low abundance with very high affinity (KD = 68 ± 7 pM). Competition studies indicate that both sites are relatively mu selective. However, several compounds clearly distinguish between the two sites. These binding studies support the concept of a unique M6G receptor responsible for its analgesic activity.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
D. M. Platt, J. K. Rowlett, S. Izenwasser, and R. D. Spealman
Opioid Partial Agonist Effects of 3-O-Methylnaltrexone in Rhesus Monkeys
J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1030 - 1039.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. L. Neilan, A. J. Janvey, E. Bolan, I. Berezowska, T. M.-D. Nguyen, P. W. Schiller, and G. W. Pasternak
Characterization of the Binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a Highly Potent Opioid Peptide
J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 430 - 436.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. A. Bowen, B. D. Fischer, N. K. Mello, and S. S. Negus
Antagonism of the Antinociceptive and Discriminative Stimulus Effects of Heroin and Morphine by 3-Methoxynaltrexone and Naltrexone in Rhesus Monkeys
J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 264 - 273.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
N. A. Martin and P. L. Prather
Interaction of Co-Expressed {micro}- and {delta}-Opioid Receptors in Transfected Rat Pituitary GH3 Cells
Mol. Pharmacol., April 1, 2001; 59(4): 774 - 783.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. Leventhal, R. M. Silva, G. C. Rossi, G. W. Pasternak, and R. J. Bodnar
Morphine-6beta -Glucuronide-Induced Hyperphagia: Characterization of Opioid Action By Selective Antagonists and Antisense Mapping in Rats
J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 538 - 544.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
I. E. Goldberg, G. C. Rossi, S. R. Letchworth, J. P. Mathis, J. Ryan-Moro, L. Leventhal, W. Su, D. Emmel, E. A. Bolan, and G. W. Pasternak
Pharmacological characterization of Endomorphin-1 and Endomorphin-2 in Mouse Brain
J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 1007 - 1013.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. P. Brown and G. W. Pasternak
3H-Naloxone Benzoylhydrazone Binding in MOR-1-Transfected Chinese Hamster Ovary Cells: Evidence for G-Protein-Dependent Antagonist Binding
J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 376 - 381.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.